Genetics - Sr Dir- San Juan Capistrano, California
Senior Director, Genetics - San Juan Capistrano, CA
Recognized by FORTUNE magazine as one of the "World's Most Admired Companies," Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that doctors, and patients need to make better healthcare decisions. They are pioneers in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.
With corporate headquarters in Secaucus, NJ, Quest Diagnostics is a Fortune 500 company traded on the New York Stock Exchange (NYSE: DGX) and included in the Dow Jones Sustainability World Index. With 2020 revenues of $9.44 Billion and approximately 50,000 employees and 6,600 patient locations across the US, Quest Diagnostics serves half of the physicians and hospitals in the US with their large variety of products and services.
The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics also provides services to employers, life insurance companies, other commercial labs, clinics, health plans, government agencies, and organizations involved in clinical trials research.
Approximately 150 million times each year, patients and their physicians rely upon Quest Diagnostics results to make important healthcare decisions and approximately one third of U.S. physicians - and many of the country's leading hospitals and health systems - relies on Quest Diagnostics healthcare information solutions to foster better patient care and outcomes.
* FORTUNE magazine's "World's Most Admired Companies" list for 7 consecutive years; one of only five companies to attain Most Admired status in the "Health Care, Pharmacy and Other Services" industry category.
* Fortune magazine's Fortune 500 list
* Forbes(r) Global 2000
* Forbes(r)' America's Best Employers List for third consecutive year
* Forbes(r) 2020 America's Best Employers for Women for second consecutive year
* S&P 500
* Barron's 500
* Member of the Dow Jones(r) Sustainability World Index
* Included in the FTSE4Good, Calvert, and Ocean Tomo sustainability indices.
* Listed in the most recent Newsweek Green Rankings
* Consistently named one of the best places to work in U.S. business journal rankings.
* Named a DiversityInc Noteworthy Company for a third consecutive year.
* Listed on the Disability Equality Index(r) (DEI), a joint initiative of the American Association of People with Disabilities (AAPD) and the US Business Leadership Network (USBLN), recognizing companies for prioritizing the inclusion of people with disabilities.
* Named Top 23 'Best Places to Work for LGBTQ Equality' in New Jersey.
* Achieved Cancer Gold Standard accreditation from the CEO Roundtable on Cancer, recognizing our actions to reduce the cancer risk of employees and their families.
* Received C. Everett Koop National Health Award for Efforts to Promote Employee Health in 2020
Diagnostic Testing Services
Quest Diagnostics is the world's leading provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. Their services range from routine blood tests -- such as total cholesterol, Pap testing and white blood cell count -- to complex, gene-based and molecular testing. They perform medical tests that aid in the diagnosis or detection of diseases, measure the progress or recovery from a disease or confirm that an individual is free from disease. In addition, they have specialized expertise in cancer, cardiovascular diseases, infectious diseases, and neurology.
In the $60 Billion and growing US Diagnostic Testing Market, Quest Diagnostics is the leader. Quest Diagnostics' reputation as a leading innovator, provider of high value, low cost solutions and its financial strength and flexibility make it well positioned to capitalize on the evolving healthcare landscape.
Quest Diagnostics' long-term strategy is to become the undisputed world leader in diagnostic testing, information, and services. To drive this profitable growth, Quest Diagnostics plans to leverage capabilities to create differentiation:
* Deliver Innovative Solutions
* Leverage their Unparalleled Access and Distribution Network
* Expand their relationships with large payors and health systems
* Deliver Superior Patient Experiences
The Senior Director, Genetics reports to the licensed Medical or Scientific Director or Chief Director and is responsible for providing technical interpretation of results and signing reports; implementing new assays, assay troubleshooting, acting as a technical consultant to operations staff and participation in QA responsibilities, and reviewing SOPs. Position may allow for some cross-functional activities in the Cytogenetics and/or Molecular Oncology laboratories. Assumes Clinical Consultant or Technical Supervisor responsibilities as assigned by the Medical Director.
* Accomplish test review and sign-out in the specified TAT.
* Assist in assay troubleshooting and implementation of new assays.
* Monitor compliance regarding a safe working environment.
* Assist, as needed, in the training of technologists.
* Observe compliance with regulatory agencies, including inspections.
* Monitor of quality assurance at all levels of practice.
* Participate in working groups of related or associated professionals.
* Represent Quest Diagnostics at professional meetings and sales events.
MD degree or Ph.D. degree in a relevant discipline.
Board eligibility or certification in the appropriate genetic subspecialty by the American Board of Medical Genetics and Genomics or equivalent.
California limited license as a clinical genetic molecular biologist (CGMB) or clinical genetic molecular biologist scientist (CGMBS), and New York Certificate of Qualification for Molecular Genetics Testing are preferred.
A minimum of 3-5 years of related experience.
Working knowledge of molecular biology and development of genotyping and NGS assays.
Knowledge in high-throughput genotyping platforms and automated sequencing methods.
Experience in data analysis and/or report sign-out in the cytogenetics and somatic cancer areas is a plus.
Highly developed verbal and written communication skills.
Demonstrated good decision-making and organizational skills.
The capability of being continuously updated in literature regarding its medical applications.
All requirements are subject to possible modifications to reasonably accommodate individuals with disabilities.
Please Log In or Register to Upload a Resume and complete the online Application by visiting careers.questdiagnostics.com , clicking "Job Search" and following the prompts. Because of the large number of applicants to job openings, Quest Diagnostics will only contact qualified candidates for interviews.
Quest Diagnostics is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran, or disability status.
All requirements are subject to possible modifications to reasonably accommodate individuals with disabilities. Quest Diagnostics is an Equal Opportunity Employer: Women / Minorities / Veterans /Disabled / Sexual Orientation / Gender Identity or Citizenship.
Internal Number: 66384
About Quest Diagnostics
We are an industry leader with a longstanding reputation for exceptional quality and stability in our market. We inspire action, illuminate answers, and advocate better health.
At Quest Diagnostics, we are dedicated to continuously improving patient health. We are the world’s leading provider of diagnostic testing, services, and information that patients and doctors rely on to make better healthcare decisions.
Each day, we impact the lives of millions, serving one in three American adults. Our continuous pursuit to discover and innovate enables us to create new solutions every day, many of which are now industry standards of care. Diagnostic tests influence about 66% of clinical decision making.